Antonios Chatzigeorgiou is an Associate Professor of Physiology at the Medical School of the National and Kapodistrian University of Athens, Greece. He studied Biology and then Medicine at the University of Athens, where he also completed his Ph.D. on the role of low-grade inflammation in the development of diabetic complications. For his postdoctoral studies, Dr. Chatzigeorgiou moved in 2011 to the Medical Faculty of the Technical University of Dresden, Germany, initially as a Postdoctoral Fellow, then as a Medical Resident and Senior Research Associate/Principal Investigator. In 2018, he moved to the position of Assistant Professor of Physiology at the Medical School of the University of Athens, and in June 2022, he was promoted to Associate Professor in the same Department. Dr. Chatzigeorgiou is also a Board-certified Medical Specialist in both Laboratory Medicine and Endocrinology. He has published more than 100 peer-reviewed articles (h-index 35, >5000 citations) and has consistently focused his research on the physiology and pathophysiology of metabolism-associated organs, such as adipose tissue and the liver. His studies have shed light on important molecular mechanisms underlying obesity- and diabetes-related complications, such as insulin resistance and non-alcoholic fatty liver disease and steatohepatitis (NAFLD/NASH), while also proposing innovative therapeutic approaches in this field. The excellent quality of his work is demonstrated by original publications as first/last author in high-impact journals (e.g., Nat. Immunol., PNAS, Hepatology, Metabolism, Endocrinology, FASEB J., Thromb. Haemost.), as well as by collaborative publications in recognized journals (Cell, Hepatology, Circ. Research, J. Immunol., JCI Insight, JBC, Mol. Cell. Biol., etc.). His achievements have been internationally recognized through numerous research awards and distinctions (e.g., European Foundation for the Study of Diabetes, European Society of Endocrinology, German Center for Diabetes Research, International Union of Physiological Sciences), and he has secured funding from multiple national and international sources [German Research Foundation (DFG), European Foundation for the Study of Diabetes (EFSD), Hellenic Foundation for Research and Innovation (HFRI), Hellenic Association for the Study of the Liver (HASL), etc.]. In addition, Dr. Chatzigeorgiou has served as a reviewer for numerous respected scientific journals and funding bodies, and he has been invited to speak at several national and international meetings and Institutes.

As a 2025-2026 Fulbright Scholar, Dr. Chatzigeorgiou will be hosted at the University of Massachusetts Chan Medical School, to conduct research in collaboration with Professor Alan Mullen, Academic Director of the Division of Gastroenterology and Mary C. DeFeudis Chair in Biomedical Research. Their project is titled: Exploring Novel Therapeutic Approaches Against Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Liver Fibrosis Utilizing Human Liver Organoids.